{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:17:26Z","timestamp":1790752646876,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006342","name":"Association Vaincre la Mucoviscidose","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adenosine triphosphate binding cassette transporter, subfamily B member 4 (ABCB4) is the transporter of phosphatidylcholine at the canalicular membrane of hepatocytes. ABCB4 deficiency, due to genetic variations, is responsible for progressive familial intrahepatic cholestasis type 3 (PFIC3) and other rare biliary diseases. Roscovitine is a molecule in clinical trial that was shown to correct the F508del variant of cystic fibrosis transmembrane conductance regulator (CFTR), another ABC transporter. In the present study, we hypothesized that roscovitine could act as a corrector of ABCB4 traffic-defective variants. Using HEK and HepG2 cells, we showed that roscovitine corrected the traffic and localisation at the plasma membrane of ABCB4-I541F, a prototypical intracellularly retained variant. However, roscovitine caused cytotoxicity, which urged us to synthesize non-toxic structural analogues. Roscovitine analogues were able to correct the intracellular traffic of ABCB4-I541F in HepG2 cells. Importantly, the phospholipid secretion activity of this variant was substantially rescued by three analogues (MRT2-235, MRT2-237 and MRT2-243) in HEK cells. We showed that these analogues also triggered the rescue of intracellular traffic and function of two other intracellularly retained ABCB4 variants, <jats:italic>i.e<\/jats:italic>. I490T and L556R. Our results indicate that structural analogues of roscovitine can rescue genetic variations altering the intracellular traffic of ABCB4 and should be considered as therapeutic means\u00a0for severe biliary diseases caused by this class of variations.<\/jats:p>","DOI":"10.1038\/s41598-019-43111-y","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T10:03:45Z","timestamp":1556618625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Structural analogues of roscovitine rescue the intracellular traffic and the function of ER-retained ABCB4 variants in cell models"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0736-614X","authenticated-orcid":false,"given":"Virginie","family":"Vauthier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amel","family":"Ben Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Elie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassima","family":"Oumata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Durand-Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Bruneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6512-5483","authenticated-orcid":false,"given":"Jean-Louis","family":"Delaunay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6469-0651","authenticated-orcid":false,"given":"Chantal","family":"Housset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7459-859X","authenticated-orcid":false,"given":"Tounsia","family":"A\u00eft-Slimane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3511-4916","authenticated-orcid":false,"given":"Laurent","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2867-0500","authenticated-orcid":false,"given":"Thomas","family":"Falgui\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,30]]},"reference":[{"key":"43111_CR1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/cphy.c120027","volume":"3","author":"JL Boyer","year":"2013","unstructured":"Boyer, J. L. Bile formation and secretion. Compr Physiol 3, 1035\u20131078 (2013).","journal-title":"Compr Physiol"},{"key":"43111_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.clinre.2014.03.001","volume":"38","author":"T Falgui\u00e8res","year":"2014","unstructured":"Falgui\u00e8res, T., A\u00eft-Slimane, T., Housset, C. & Maurice, M. ABCB4: insights from pathobiology into therapy. Clin Res Hepatol Gastroenterol 38, 557\u2013563 (2014).","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"43111_CR3","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1172\/JCI105794","volume":"47","author":"WH Admirand","year":"1968","unstructured":"Admirand, W. H. & Small, D. M. The physicochemical basis of cholesterol gallstone formation in man. J Clin Invest 47, 1043\u20131052 (1968).","journal-title":"J Clin Invest"},{"key":"43111_CR4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S1388-1981(00)00053-6","volume":"1486","author":"P Borst","year":"2000","unstructured":"Borst, P., Zelcer, N. & van Helvoort, A. ABC transporters in lipid transport. Biochim Biophys Acta 1486, 128\u2013144 (2000).","journal-title":"Biochim Biophys Acta"},{"issue":"Suppl","key":"43111_CR5","doi-asserted-by":"publisher","first-page":"S406","DOI":"10.1194\/jlr.R800075-JLR200","volume":"50","author":"DQ Wang","year":"2009","unstructured":"Wang, D. Q., Cohen, D. E. & Carey, M. C. Biliary lipids and cholesterol gallstone disease. J Lipid Res 50(Suppl), S406\u2013411 (2009).","journal-title":"J Lipid Res"},{"key":"43111_CR6","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1093\/hmg\/9.8.1209","volume":"9","author":"PH Dixon","year":"2000","unstructured":"Dixon, P. H. et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet 9, 1209\u20131217 (2000).","journal-title":"Hum Mol Genet"},{"key":"43111_CR7","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1053\/gast.2001.23984","volume":"120","author":"E Jacquemin","year":"2001","unstructured":"Jacquemin, E. et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 120, 1448\u20131458 (2001).","journal-title":"Gastroenterology"},{"key":"43111_CR8","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1053\/gast.2001.23947","volume":"120","author":"O Rosmorduc","year":"2001","unstructured":"Rosmorduc, O., Hermelin, B. & Poupon, R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 120, 1459\u20131467 (2001).","journal-title":"Gastroenterology"},{"key":"43111_CR9","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/hep.28300","volume":"63","author":"JL Delaunay","year":"2016","unstructured":"Delaunay, J. L. et al. A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3. Hepatology 63, 1620\u20131631 (2016).","journal-title":"Hepatology"},{"key":"43111_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2017.02.020","volume":"136","author":"V Vauthier","year":"2017","unstructured":"Vauthier, V., Housset, C. & Falguieres, T. Targeted pharmacotherapies for defective ABC transporters. Biochemical pharmacology 136, 1\u201311 (2017).","journal-title":"Biochemical pharmacology"},{"issue":"Suppl 1","key":"43111_CR11","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S2210-7401(12)70015-3","volume":"36","author":"R Poupon","year":"2012","unstructured":"Poupon, R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: An overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 36(Suppl 1), S3\u2013S12 (2012).","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"43111_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-2-29","volume":"2","author":"O Rosmorduc","year":"2007","unstructured":"Rosmorduc, O. & Poupon, R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3\/ABCB4 gene. Orphanet J Rare Dis 2, 29 (2007).","journal-title":"Orphanet J Rare Dis"},{"key":"43111_CR13","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3748\/wjg.15.2049","volume":"15","author":"V Geenes","year":"2009","unstructured":"Geenes, V. & Williamson, C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 15, 2049\u20132066 (2009).","journal-title":"World J Gastroenterol"},{"key":"43111_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/hep.510250303","volume":"25","author":"E Jacquemin","year":"1997","unstructured":"Jacquemin, E. et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 25, 519\u2013523 (1997).","journal-title":"Hepatology"},{"key":"43111_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-4-1","volume":"4","author":"A Davit-Spraul","year":"2009","unstructured":"Davit-Spraul, A., Gonzales, E., Baussan, C. & Jacquemin, E. Progressive familial intrahepatic cholestasis. Orphanet journal of rare diseases 4, 1 (2009).","journal-title":"Orphanet journal of rare diseases"},{"key":"43111_CR16","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/hep.28929","volume":"65","author":"JL Delaunay","year":"2017","unstructured":"Delaunay, J. L. et al. Functional defect of variants in the adenosine triphosphate-binding sites of ABCB4 and their rescue by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770). Hepatology 65, 560\u2013570 (2017).","journal-title":"Hepatology"},{"key":"43111_CR17","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1074\/jbc.M111.275438","volume":"287","author":"J Gautherot","year":"2012","unstructured":"Gautherot, J. et al. Effects of Cellular, chemical and pharmacological chaperones on the rescue of a trafficking-defective mutant of the ATP-binding cassette transporters ABCB1\/ABCB4. J Biol Chem 287, 5070\u20135078 (2012).","journal-title":"J Biol Chem"},{"key":"43111_CR18","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1002\/hep.26970","volume":"59","author":"EJ Andress","year":"2014","unstructured":"Andress, E. J. et al. A molecular mechanistic explanation for the spectrum of cholestatic disease caused by the S320F variant of ABCB4. Hepatology 59, 1921\u20131931 (2014).","journal-title":"Hepatology"},{"key":"43111_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/srep26872","volume":"6","author":"HJ Park","year":"2016","unstructured":"Park, H. J. et al. Functional characterization of ABCB4 mutations found in progressive familial intrahepatic cholestasis type 3. Sci Rep 6, 26872 (2016).","journal-title":"Sci Rep"},{"key":"43111_CR20","first-page":"543","volume":"36","author":"BM Foxwell","year":"1989","unstructured":"Foxwell, B. M., Mackie, A., Ling, V. & Ryffel, B. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol 36, 543\u2013546 (1989).","journal-title":"Mol Pharmacol"},{"key":"43111_CR21","doi-asserted-by":"crossref","first-page":"16509","DOI":"10.1016\/S0021-9258(17)46252-1","volume":"265","author":"I Tamai","year":"1990","unstructured":"Tamai, I. & Safa, A. R. Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. J Biol Chem 265, 16509\u201316513 (1990).","journal-title":"J Biol Chem"},{"key":"43111_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1432-1033.1997.t01-2-00527.x","volume":"243","author":"L Meijer","year":"1997","unstructured":"Meijer, L. et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. European journal of biochemistry 243, 527\u2013536 (1997).","journal-title":"European journal of biochemistry"},{"key":"43111_CR23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1021\/ar0201198","volume":"36","author":"L Meijer","year":"2003","unstructured":"Meijer, L. & Raymond, E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Accounts of chemical research 36, 417\u2013425 (2003).","journal-title":"Accounts of chemical research"},{"key":"43111_CR24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000444256","volume":"8","author":"L Meijer","year":"2016","unstructured":"Meijer, L. et al. Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis. Journal of innate immunity 8, 330\u2013349 (2016).","journal-title":"Journal of innate immunity"},{"key":"43111_CR25","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.1111\/bph.12859","volume":"171","author":"C Norez","year":"2014","unstructured":"Norez, C. et al. Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism. British journal of pharmacology 171, 4831\u20134849 (2014).","journal-title":"British journal of pharmacology"},{"key":"43111_CR26","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/hep.22775","volume":"49","author":"JL Delaunay","year":"2009","unstructured":"Delaunay, J. L. et al. A missense mutation in ABCB4 gene involved in progressive familial intrahepatic cholestasis type 3 leads to a folding defect that can be rescued by low temperature. Hepatology 49, 1218\u20131227 (2009).","journal-title":"Hepatology"},{"key":"43111_CR27","first-page":"652","volume":"68","author":"R Sormunen","year":"1993","unstructured":"Sormunen, R., Eskelinen, S. & Lehto, V. P. Bile canaliculus formation in cultured HEPG2 cells. Laboratory investigation; a journal of technical methods and pathology 68, 652\u2013662 (1993).","journal-title":"Laboratory investigation; a journal of technical methods and pathology"},{"key":"43111_CR28","doi-asserted-by":"publisher","first-page":"31220","DOI":"10.1074\/jbc.M500805200","volume":"280","author":"L Tang","year":"2005","unstructured":"Tang, L. et al. Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. J Biol Chem 280, 31220\u201331229 (2005).","journal-title":"J Biol Chem"},{"key":"43111_CR29","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.1096\/fj.12-212985","volume":"26","author":"K Bettayeb","year":"2012","unstructured":"Bettayeb, K. et al. Small-molecule inducers of Abeta-42 peptide production share a common mechanism of action. Faseb j 26, 5115\u20135123 (2012).","journal-title":"Faseb j"},{"key":"43111_CR30","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jhep.2012.01.025","volume":"57","author":"D Tougeron","year":"2012","unstructured":"Tougeron, D., Fotsing, G., Barbu, V. & Beauchant, M. ABCB4\/MDR3 gene mutations and Cholangiocarcinomas. J Hepatol 57, 467\u2013468 (2012).","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"43111_CR31","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/S2210-7401(12)70018-9","volume":"36","author":"E Jacquemin","year":"2012","unstructured":"Jacquemin, E. Progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol 36(Suppl 1), S26\u201335 (2012).","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"43111_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.5500\/wjt.v6.i2.278","volume":"6","author":"A Mehl","year":"2016","unstructured":"Mehl, A., Bohorquez, H., Serrano, M. S., Galliano, G. & Reichman, T. W. Liver transplantation and the management of progressive familial intrahepatic cholestasis in children. World J Transplant 6, 278\u2013290 (2016).","journal-title":"World J Transplant"},{"key":"43111_CR33","doi-asserted-by":"publisher","first-page":"S626","DOI":"10.1016\/S0168-8278(18)31509-5","volume":"68","author":"D van Wessel","year":"2018","unstructured":"van Wessel, D. et al. The natural course of FIC1 deficiency and BSEP deficiency: Initial results from the NAPPED-consortium (Natural course and Prognosis of PFIC and Effect of biliary Diversion) [ABSTRACT]. Journal of Hepatology 68, S626\u2013S627 (2018).","journal-title":"Journal of Hepatology"},{"key":"43111_CR34","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.jpeds.2013.12.032","volume":"164","author":"S Naoi","year":"2014","unstructured":"Naoi, S. et al. Improved liver function and relieved pruritus after 4-phenylbutyrate therapy in a patient with progressive familial intrahepatic cholestasis type 2. J Pediatr 164, 1219\u20131227 (2014).","journal-title":"J Pediatr"},{"key":"43111_CR35","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/hep.27767","volume":"62","author":"E Gonzales","year":"2015","unstructured":"Gonzales, E. et al. Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate. Hepatology 62, 558\u2013566 (2015).","journal-title":"Hepatology"},{"key":"43111_CR36","doi-asserted-by":"publisher","first-page":"e0150098","DOI":"10.1371\/journal.pone.0150098","volume":"11","author":"R Gordo-Gilart","year":"2016","unstructured":"Gordo-Gilart, R., Andueza, S., Hierro, L., Jara, P. & Alvarez, L. Functional Rescue of Trafficking-Impaired ABCB4 Mutants by Chemical Chaperones. PLoS One 11, e0150098 (2016).","journal-title":"PLoS One"},{"key":"43111_CR37","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/MPG.0000000000001082","volume":"62","author":"BL Shneider","year":"2015","unstructured":"Shneider, B. L. & Vockley, J. Possible Phenylacetate Hepatotoxicity During 4-Phenylbutyrate Therapy of Byler Disease. J Pediatr Gastroenterol Nutr 62, 424\u2013428 (2015).","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"43111_CR38","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2147\/PPA.S136754","volume":"11","author":"L Pena-Quintana","year":"2017","unstructured":"Pena-Quintana, L., Llarena, M., Reyes-Suarez, D. & Aldamiz-Echevarria, L. Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: patient perspectives. Patient preference and adherence 11, 1489\u20131496 (2017).","journal-title":"Patient preference and adherence"},{"key":"43111_CR39","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1432-1033.1997.0518a.x","volume":"243","author":"WF De Azevedo","year":"1997","unstructured":"De Azevedo, W. F. et al. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. European journal of biochemistry 243, 518\u2013526 (1997).","journal-title":"European journal of biochemistry"},{"key":"43111_CR40","doi-asserted-by":"publisher","first-page":"31208","DOI":"10.1074\/jbc.M500806200","volume":"280","author":"S Bach","year":"2005","unstructured":"Bach, S. et al. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 280, 31208\u201331219 (2005).","journal-title":"J Biol Chem"},{"key":"43111_CR41","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1055\/s-0038-1667299","volume":"38","author":"MC Reichert","year":"2018","unstructured":"Reichert, M. C. & Lammert, F. ABCB4 Gene Aberrations in Human Liver Disease: An Evolving Spectrum. Seminars in liver disease 38, 299\u2013307 (2018).","journal-title":"Seminars in liver disease"},{"key":"43111_CR42","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1055\/s-0030-1253223","volume":"30","author":"A Davit-Spraul","year":"2010","unstructured":"Davit-Spraul, A., Gonzales, E., Baussan, C. & Jacquemin, E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis 30, 134\u2013146 (2010).","journal-title":"Semin Liver Dis"},{"key":"43111_CR43","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/hep.26424","volume":"58","author":"R Poupon","year":"2013","unstructured":"Poupon, R. et al. Genotype-phenotype relationships in the low-phospholipid associated cholelithiasis syndrome. A study of 156 consecutive patients. Hepatology 58, 1105\u20131110 (2013).","journal-title":"Hepatology"},{"key":"43111_CR44","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.dld.2016.10.006","volume":"49","author":"Y Bacq","year":"2017","unstructured":"Bacq, Y. et al. Ursodeoxycholic acid therapy in intrahepatic cholestasis of pregnancy: Results in real-world conditions and factors predictive of response to treatment. Dig Liver Dis 49, 63\u201369 (2017).","journal-title":"Dig Liver Dis"},{"key":"43111_CR45","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1053\/jhep.2001.24034","volume":"33","author":"U Beuers","year":"2001","unstructured":"Beuers, U. et al. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 33, 1206\u20131216 (2001).","journal-title":"Hepatology"},{"key":"43111_CR46","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/labinvest.3700371","volume":"86","author":"F Dombrowski","year":"2006","unstructured":"Dombrowski, F., Stieger, B. & Beuers, U. Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver. Lab Invest 86, 166\u2013174 (2006).","journal-title":"Lab Invest"},{"key":"43111_CR47","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.27834","volume":"62","author":"S Varma","year":"2015","unstructured":"Varma, S. et al. Retargeting of bile salt export pump and favorable outcome in children with progressive familial intrahepatic cholestasis type 2. Hepatology 62, 198\u2013206 (2015).","journal-title":"Hepatology"},{"key":"43111_CR48","first-page":"135","volume":"3","author":"J Cicenas","year":"2015","unstructured":"Cicenas, J. et al. Roscovitine in cancer and other diseases. Annals of translational medicine 3, 135 (2015).","journal-title":"Annals of translational medicine"},{"key":"43111_CR49","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1007\/s00018-017-2472-6","volume":"74","author":"EJ Andress","year":"2017","unstructured":"Andress, E. J., Nicolaou, M., McGeoghan, F. & Linton, K. J. ABCB4 missense mutations D243A, K435T, G535D, I490T, R545C, and S978P significantly impair the lipid floppase and likely predispose to secondary pathologies in the human population. Cell Mol Life Sci 74, 2513\u20132524 (2017).","journal-title":"Cell Mol Life Sci"},{"key":"43111_CR50","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/hep.27170","volume":"60","author":"J Gautherot","year":"2014","unstructured":"Gautherot, J. et al. Phosphorylation of ABCB4 impacts its function: Insights from disease-causing mutations. Hepatology 60, 610\u2013621 (2014).","journal-title":"Hepatology"},{"key":"43111_CR51","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/227680a0","volume":"227","author":"UK Laemmli","year":"1970","unstructured":"Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680\u2013685 (1970).","journal-title":"Nature"},{"key":"43111_CR52","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-1-61779-080-5_20","volume":"731","author":"J van Meerloo","year":"2011","unstructured":"van Meerloo, J., Kaspers, G. J. & Cloos, J. Cell sensitivity assays: the MTT assay. Methods Mol Biol 731, 237\u2013245 (2011).","journal-title":"Methods Mol Biol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43111-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43111-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43111-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T09:05:08Z","timestamp":1671267908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43111-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,30]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["43111"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-43111-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,30]]},"assertion":[{"value":"13 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As co-founder of ManRos Therapeutics, L.M. is paid and has stocks from this company. J.E. and N.O. are employees of ManRos Therapeutics and are paid by this company.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6653"}}